Overview

A Study of KHK4827 in Subjects With Axial Spondyloarthritis (axSpA)

Status:
Completed
Trial end date:
2019-09-23
Target enrollment:
0
Participant gender:
All
Summary
To evaluate the efficacy of KHK4827 in axSpA (ankylosing spondylitis [AS] and non-radiographic axial spondyloarthritis [nr-axSpA]) subjects compared to placebo, as measured by the proportion of axSpA subjects achieving an Assessment of SpondyloArthritis international Society (ASAS) 40 response at week 16.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Kyowa Hakko Kirin Co., Ltd
Kyowa Kirin Co., Ltd.
Treatments:
Brodalumab
Criteria
Inclusion Criteria:

- Subject with age at onset <45 years and continuous chronic back pain for ≥ 3 months
fulfills the ASAS classification criteria of axial spondyloarthritis (with the
exception of the Crohn's disease)

- Subject has Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ≥ 4 at
screening and enrollment

- Subject has spinal pain score (BASDAI question #2) ≥ 4 at screening and enrollment

- Subject has had adequate therapy with non-steroidal anti-inflammatory drugs (oral
NSAIDs) for back pain for at least 3 months with inadequate treatment response before
enrollment

Exclusion Criteria:

- Complete ankylosis (fusion) of the spine

- Subject with active ongoing inflammatory diseases other than axSpA that might confound
the evaluation of KHK4827 therapy, including reactive arthritis, spondyloarthritis
associated with inflammatory bowel disease, SAPHO syndrome (pustulotic
arthro-osteitis), fibromyalgia, ankylosing spinal hyperostosis, osteitis condensans
ilii, spondylosis deformans, or osteoarthritis sacroiliac joint disease

- Subject has a prior history of >1 anti-TNF therapy

- Subject has a history or evidence of suicidal ideation (severity of 4 or 5) or any
suicidal behavior based on an assessment with the Columbia-Suicide Severity Rating
Scale (C-SSRS) at enrollment

- Subject has a history or evidence of a psychiatric disorder, alcohol and/or substance
abuse

- Subject has severe depression based on a total score of ≥ 15 on the Patient Health
Questionnaire-8 (PHQ-8) at enrollment (note: subjects with a total score of 10 to 14
on the PHQ-8 should be referred to a mental health care professional)